Developer docs
API playgroundTry for free, no card

Search company profiles

Zomedica

Full company profile

uuid0000ho2

Namestring
Zomedica
Legal namestring
Zomedica Inc.
Websiteurl
zomedica.com
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Zomedica is a publicly traded animal health company (NYSE American: ZOM; OTCQB: ZOMDF) headquartered in Ann Arbor, Michigan, that develops and sells diagnostic and therapeutic products for companion animal and equine veterinarians in the United States, Canada, and the European Union. Its portfolio spans four sub-brands: ZOM•Dx diagnostic platforms (TRUFORMA biosensor testing, TRUVIEW automated digital microscopy with AI-driven cytology interpretation, VETGuardian PLUS zero-touch vital signs monitoring, and SonoView); Assisi tPEMF therapy products (Loop, Loop Lounge, DentaLOOP, Calmer Canine) for drug-free pain management; PulseVet shock wave therapy systems for regenerative equine and small-animal treatment; and VETIGEL plant-based hemostatic gel for surgical bleeding control.

The company generates revenue primarily through hardware sales of its diagnostic and therapeutic devices, paired with a recurring consumables model on TRUFORMA analyzer placements and a contract manufacturing arrangement (Rahm Sensor Development/Cell-Guardian) that leverages its Roswell, Georgia and Plymouth, Minnesota manufacturing facilities. Zomedica goes to market through a direct US sales force targeting companion animal and equine clinics, supplemented by channel partnerships — Moichor for US TRUVIEW distribution, Grovet b.v. for the EU, UXR for Canada, and Boehringer Ingelheim Animal Health for equine PPID diagnostic testing under a reimbursement program.

Zomedica built its portfolio primarily through acquisition, including Pulse Veterinary Technologies (2021, $70.9 million), Revo Squared (2022), Assisi Animal Health (2022), Structured Monitoring Products/PIMS (2023), and Qorvo Biotech (2023). The company reported $32.0 million in full-year 2025 revenue (17% year-over-year growth) and $8.8 million in Q1 2026 revenue (35% year-over-year growth), marking 21 consecutive quarters of record year-over-year revenue, with 68% gross margins in 2025 and approximately $48 million in liquidity as of March 31, 2026.

Short descriptiontext

Zomedica is a publicly traded animal health company that develops and sells diagnostic platforms (TRUFORMA, TRUVIEW, VETGuardian PLUS) and therapeutic devices (Assisi tPEMF, PulseVet shock wave, VETIGEL) to companion animal and equine veterinarians across the US, Canada, and the EU via direct sales and distribution partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersAnn Arbor, United States
HQ citystring
Ann Arbor
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
veterinary diagnostics, veterinary therapeutics, point-of-care testing, animal health devices, veterinary medical equipment
Industry3 codes
1Companion Animal Therapeutics (Rx)
CodeHLAMAEAAPrimaryYes
2Equine Therapeutics (Rx)
CodeHLAMAEACPrimaryNo
3Pain Management, Anesthesia & Critical Care Drugs
CodeHLAMAEAFPrimaryNo
NAICS code2 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Veterinary Services541940
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Pharmaceutical Preparations2834
Product category
Veterinary Diagnostics and Therapeutics
GTM motion5 records

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Equipment and Consumables
TypeHardware Sales
Description

Point-of-care diagnostic equipment (TRUFORMA, TRUVIEW, VETGuardian) sold alongside recurring consumable revenue through analyzer and cartridge system. Each system placement generates recurring consumables revenue.

ad-hoc-news.de
2Therapeutic Devices
TypeHardware Sales
Description

Sale of therapeutic devices including PulseVet shock wave system, Assisi tPEMF products (LOOP, Loop Lounge, DentaLOOP, Calmer Canine), and VETIGEL hemostatic gel.

zomedica.com
3Contract Manufacturing Services
TypeManaged Services
Description

Leverages existing manufacturing infrastructure to generate contract-based revenue beyond core animal health business through OEM manufacturing partnerships (Rahm sensor manufacturing deal for Cell-Guardian).

stocktitan.net
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain
Pricing details1 tier
1Diagnostic platforms with recurring consumables
ModelHybridBilling cadencePay-as-you-go
Notes

Point-of-care diagnostic equipment sold alongside recurring consumable revenue model through analyzer and cartridge system.

ad-hoc-news.de
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1ZOM•Dx
Description

Diagnostic products including TRUFORMA, TRUVIEW, VETGuardian PLUS, and SonoView platforms for veterinary diagnostics

zomedica.com
+3 more records
Core offering1 text field

Zomedica develops, manufactures, and sells diagnostic and therapeutic medical devices for veterinary clinics treating companion animals (dogs, cats) and equine patients. Its product portfolio includes point-of-care biosensor diagnostic platforms (TRUFORMA), automated digital cytology microscopes (TRUVIEW), zero-touch patient vital signs monitors (VETGuardian PLUS), targeted pulsed electromagnetic field therapy devices (Assisi LOOP line), shock wave therapy systems (PulseVet), and hemostatic gels (VETIGEL). Revenue is generated through instrument placements combined with recurring consumable cartridge sales, alongside therapeutic device sales.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 68% gross margin achieved in 2025
+4 more records
Product overview1 text field

Zomedica is an animal health company offering an integrated portfolio of diagnostic and therapeutic products for equine and companion animals. The product portfolio consists of multiple distinct platforms and product lines: (1) ZOM-Dx diagnostic division including TRUFORMA (point-of-care biosensor testing platform), TRUVIEW (fully automated digital microscopy with AI), VETGuardian PLUS (zero-touch vital signs monitoring), and SonoView; (2) Assisi tPEMF therapy line including Assisi LOOP, Loop Lounge, DentaLOOP, and Calmer Canine for drug-free pain management; (3) PulseVet shock wave therapy systems including the PulseVet device, X-Trode, and Equine Trode Set for regeneration; and (4) VETIGEL hemostatic gel for bleeding control. The company operates a consumables/revenue model alongside device placements, with products serving both companion animal and equine veterinary markets.

Product and service10 records
1TRUFORMA
CategoryDiagnostic platform
Description

In-clinic biosensor testing platform that enables point-of-care diagnostic testing with rapid results for veterinary applications including endocrine testing (ACTH for PPID diagnosis, progesterone for reproductive health), cardiac biomarkers (NT-proBNP), and other diagnostic assays. Sold to veterinary clinics with recurring cartridge-based consumables revenue.

2TRUVIEW
CategoryDiagnostic platform
Description

The only fully automated digital microscope that prepares and digitizes hematology and cytology slides for review in minutes. Includes AI-powered diagnostic interpretation for automated analysis of hematology blood films with skin and ear cytology support.

3VETGuardian PLUS
CategoryMonitoring platform
Description

Zero-touch vital signs remote monitor that ensures pets are safe and supervised from intake to discharge, featuring non-contact monitoring, live video with night vision, and thermal imaging capabilities for veterinary clinics.

4SonoView
CategoryDiagnostic platform
Description

Diagnostic platform that is part of ZOM-Dx portfolio for veterinary ultrasound or imaging diagnostics.

5Assisi LOOP
CategoryTherapeutic device
Description

Portable, versatile, drug-free tPEMF therapy device clinically proven to decrease pain and inflammation in pets. Part of Assisi's targeted pulsed electromagnetic field therapy product line for veterinary use.

6Loop Lounge
CategoryTherapeutic device
Description

Rechargeable therapy pad offering total body drug-free relief from pain and inflammation for cats and dogs of all sizes using tPEMF technology.

7DentaLOOP
CategoryTherapeutic device
Description

Specialized tPEMF therapy device engineered for treating dental and oral pain in pets, applying proven Assisi LOOP technology in a design specifically for oral applications.

8Calmer Canine
CategoryTherapeutic device
Description

Drug-free targeted PEMF therapy device clinically proven to offer long-term relief from canine separation anxiety.

9PulseVet Shock Wave System
CategoryTherapeutic device
Description

Leading veterinary shock wave therapy device for regeneration, featuring swivel screen, Bluetooth operation, and preset treatment parameters. Backed by over 20 years of clinical research supporting shock wave therapy effectiveness.

10VETIGEL Hemostatic Gel
CategoryTherapeutic product
Description

Plant-based hemostatic gel that stops bleeding in less than ten seconds, potentially reducing blood loss, anesthesia time, and improving patient outcomes. Supplied in pre-filled syringes ready for immediate use in veterinary surgery.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-06-25
Description

Renewed alliance with Fear Free, LLC to continue promoting low-stress veterinary care and pet wellbeing through Assisi Loop tPEMF therapy products. Partnership focuses on educating veterinary professionals on stress-reducing protocols and expanding awareness of non-invasive treatment options.

2United States Eventing Association (USEA)
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-05-20
Description

Renewed sponsorship agreement maintaining PulseVet's designation as the 'Official Shock Wave of the USEA' for another year. Partnership supports USEA programs focused on educating and celebrating riders, owners, trainers, and veterinarians within the sport of Eventing.

stocktitan.net
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-18
Description

Strategic collaboration to integrate Zomedica's TRUFORMA diagnostic platform into Boehringer Ingelheim's idPPID awareness and testing program for pituitary pars intermedia dysfunction in horses. Boehringer will reimburse participating veterinarians for diagnostic testing, expand Zomedica's installed base, and drive recurring cartridge revenue. PPID affects approximately 20-25% of horses over 15 years of age.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-18
Description

Collaboration where Boehringer Ingelheim will reimburse veterinarians for diagnostic testing performed with Zomedica's TRUFORMA platform and provide no-cost analyzer placements in equine veterinary practices, accelerating TRUFORMA adoption.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-25
Description

Commercial distribution agreement with Moichor, a veterinary pathology services provider, for TRUVIEW digital microscopy platform. Co-branded systems integrate Moichor's proprietary AI engine and board-certified pathology services for point-of-care veterinary customers nationwide, spanning companion animal and exotic animal practices.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-01-22
Description

Contract manufacturing and services agreement to manufacture Cell-Guardian, a personnel monitoring device for high-risk environments such as correctional settings. Zomedica leverages existing manufacturing infrastructure to generate contract-based revenue and improve asset utilization.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-15
Description

Expanded distribution agreement with Grovet b.v. to include Zomedica's diagnostic and therapeutic device products across the European Union, strengthening Zomedica's presence in the European veterinary market.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-10
Description

Expanded distribution agreement with UXR in Canada for Zomedica's diagnostic and therapeutic products, expanding market reach in the Canadian veterinary market.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

IDEXX is the dominant veterinary diagnostics company with reference lab services, in-clinic analyzers (Catalyst, ProCyte, SNAP), and a broad assay menu. It is the primary competitive benchmark for Zomedica's TRUFORMA and TRUVIEW platforms, both directly and via former Zomedica executives with IDEXX backgrounds.

TypeDirect peer
Description

Antech is the largest veterinary reference laboratory in North America and offers in-clinic diagnostics, imaging, and teleconsultation. Several Zomedica leaders (Paul Tye, Adrienne Bricaud) previously held senior roles at Antech, underscoring the direct competitive and customer overlap with Zomedica's diagnostic offerings.

TypeDirect peer
Description

Heska specialized in veterinary in-clinic diagnostics (chemistry, hematology, immunoassay) and point-of-care testing before being acquired by Mars Petcare. It is a direct competitor to Zomedica's TRUFORMA platform and shares target customers (US companion animal clinics).

TypeBroad incumbent
Description

Zoetis is the world's largest animal health company with diagnostics, devices, pharmaceuticals, and vaccines across companion and livestock animals. Zomedica's VP of Corporate & Strategic Partnerships came from Zoetis, and Zoetis represents both a competitor (in therapeutic devices and diagnostics) and a potential strategic acquirer.

TypeBroad incumbent
Description

Elanco is a major global animal health company offering companion animal and livestock therapeutics, vaccines, and diagnostics. It is a broad incumbent comparable to Zomedica's therapeutic device and diagnostic portfolio, with substantially greater scale and distribution reach.

TypeBroad incumbent
Description

Dechra (acquired by EQT) is a specialty veterinary pharmaceuticals company focused on companion animal endocrinology, dermatology, and pain management. Its pain-management focus is comparable to Zomedica's Assisi tPEMF and PulseVet therapeutic franchises.

TypeBroad incumbent
Description

Virbac is a global animal health company providing pharmaceuticals, vaccines, and diagnostics for companion and production animals. Comparable to Zomedica's equine and companion animal therapeutic portfolio, though with a much broader product range and geographic footprint.

TypeDirect peer
Description

Covetrus is a leading distributor of veterinary products, services, and technologies, including in-clinic diagnostic platforms. Comparable to Zomedica on the distribution side of the veterinary diagnostic value chain and a potential channel partner or competitive threat to direct sales.

TypeBroad incumbent
Description

Vetoquinol is a French veterinary pharmaceutical company specializing in companion animal therapeutics with growing presence in the US. Comparable to Zomedica on equine and companion animal therapeutic devices, though primarily a pharmaceutical rather than device company.

TypeEmerging player
Description

PetIQ is a US pet health and wellness company offering veterinary products, OTC supplements, and clinic services. While focused on different categories (preventives and wellness), it overlaps with Zomedica on the broader US companion animal health opportunity and similar end-customer base of pet owners and vets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Zomedica

Veterinary Diagnostics and Therapeuticszomedica.com

Zomedica is a publicly traded animal health company that develops and sells diagnostic platforms (TRUFORMA, TRUVIEW, VETGuardian PLUS) and therapeutic devices (Assisi tPEMF, PulseVet shock wave, VETIGEL) to companion animal and equine veterinarians across the US, Canada, and the EU via direct sales and distribution partners.

What Zomedica does

Zomedica is a publicly traded animal health company (NYSE American: ZOM; OTCQB: ZOMDF) headquartered in Ann Arbor, Michigan, that develops and sells diagnostic and therapeutic products for companion animal and equine veterinarians in the United States, Canada, and the European Union. Its portfolio spans four sub-brands: ZOM•Dx diagnostic platforms (TRUFORMA biosensor testing, TRUVIEW automated digital microscopy with AI-driven cytology interpretation, VETGuardian PLUS zero-touch vital signs monitoring, and SonoView); Assisi tPEMF therapy products (Loop, Loop Lounge, DentaLOOP, Calmer Canine) for drug-free pain management; PulseVet shock wave therapy systems for regenerative equine and small-animal treatment; and VETIGEL plant-based hemostatic gel for surgical bleeding control.

The company generates revenue primarily through hardware sales of its diagnostic and therapeutic devices, paired with a recurring consumables model on TRUFORMA analyzer placements and a contract manufacturing arrangement (Rahm Sensor Development/Cell-Guardian) that leverages its Roswell, Georgia and Plymouth, Minnesota manufacturing facilities. Zomedica goes to market through a direct US sales force targeting companion animal and equine clinics, supplemented by channel partnerships — Moichor for US TRUVIEW distribution, Grovet b.v. for the EU, UXR for Canada, and Boehringer Ingelheim Animal Health for equine PPID diagnostic testing under a reimbursement program.

Zomedica built its portfolio primarily through acquisition, including Pulse Veterinary Technologies (2021, $70.9 million), Revo Squared (2022), Assisi Animal Health (2022), Structured Monitoring Products/PIMS (2023), and Qorvo Biotech (2023). The company reported $32.0 million in full-year 2025 revenue (17% year-over-year growth) and $8.8 million in Q1 2026 revenue (35% year-over-year growth), marking 21 consecutive quarters of record year-over-year revenue, with 68% gross margins in 2025 and approximately $48 million in liquidity as of March 31, 2026.

Zomedica firmographics

Firmographics
Name
Zomedica
Legal name
Zomedica Inc.
Website
https://zomedica.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Short description
Zomedica is a publicly traded animal health company that develops and sells diagnostic platforms (TRUFORMA, TRUVIEW, VETGuardian PLUS) and therapeutic devices (Assisi tPEMF, PulseVet shock wave, VETIGEL) to companion animal and equine veterinarians across the US, Canada, and the EU via direct sales and distribution partners.
Ownership category
akta.pro rank

Zomedica industry classification

Industry
Product category
Veterinary Diagnostics and Therapeutics
NAICS
Medical Equipment and Supplies Manufacturing (3391), Veterinary Services (541940)
SIC
Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)
akta.pro primary industry
Companion Animal Therapeutics (Rx) (HLAMAEAA)
akta.pro secondary industries
Equine Therapeutics (Rx) (HLAMAEAC), Pain Management, Anesthesia & Critical Care Drugs (HLAMAEAF)

Keywords

  • Veterinary diagnostics
  • Veterinary therapeutics
  • Point-of-care testing
  • Animal health devices
  • Veterinary medical equipment

Where Zomedica is headquartered

Location

Headquarters

HQ city
Ann Arbor
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Zomedica business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain

Revenue model

  1. Diagnostic Equipment and Consumables: Point-of-care diagnostic equipment (TRUFORMA, TRUVIEW, VETGuardian) sold alongside recurring consumable revenue through analyzer and cartridge system. Each system placement generates recurring consumables revenue.
  2. Therapeutic Devices: Sale of therapeutic devices including PulseVet shock wave system, Assisi tPEMF products (LOOP, Loop Lounge, DentaLOOP, Calmer Canine), and VETIGEL hemostatic gel.
  3. Contract Manufacturing Services: Leverages existing manufacturing infrastructure to generate contract-based revenue beyond core animal health business through OEM manufacturing partnerships (Rahm sensor manufacturing deal for Cell-Guardian).

Pricing tiers

ModelBillingPrice
HybridPay-as-you-goDiagnostic platforms with recurring consumables

Go-to-market motion5 records

Distribution channels5 records

Marketing channels6 records

Zomedica product offering

Product offering

Core offering

Zomedica develops, manufactures, and sells diagnostic and therapeutic medical devices for veterinary clinics treating companion animals (dogs, cats) and equine patients. Its product portfolio includes point-of-care biosensor diagnostic platforms (TRUFORMA), automated digital cytology microscopes (TRUVIEW), zero-touch patient vital signs monitors (VETGuardian PLUS), targeted pulsed electromagnetic field therapy devices (Assisi LOOP line), shock wave therapy systems (PulseVet), and hemostatic gels (VETIGEL). Revenue is generated through instrument placements combined with recurring consumable cartridge sales, alongside therapeutic device sales.

Product overview

Zomedica is an animal health company offering an integrated portfolio of diagnostic and therapeutic products for equine and companion animals. The product portfolio consists of multiple distinct platforms and product lines: (1) ZOM-Dx diagnostic division including TRUFORMA (point-of-care biosensor testing platform), TRUVIEW (fully automated digital microscopy with AI), VETGuardian PLUS (zero-touch vital signs monitoring), and SonoView; (2) Assisi tPEMF therapy line including Assisi LOOP, Loop Lounge, DentaLOOP, and Calmer Canine for drug-free pain management; (3) PulseVet shock wave therapy systems including the PulseVet device, X-Trode, and Equine Trode Set for regeneration; and (4) VETIGEL hemostatic gel for bleeding control. The company operates a consumables/revenue model alongside device placements, with products serving both companion animal and equine veterinary markets.

Differentiator

Problem solved

Functional benefit

Brands

  • ZOM•Dx: Diagnostic products including TRUFORMA, TRUVIEW, VETGuardian PLUS, and SonoView platforms for veterinary diagnostics
  • Assisi
  • PulseVet
  • VETIGEL

Products and services

  • TRUFORMA In-clinic biosensor testing platform that enables point-of-care diagnostic testing with rapid results for veterinary applications including endocrine testing (ACTH for PPID diagnosis, progesterone for reproductive health), cardiac biomarkers (NT-proBNP), and other diagnostic assays. Sold to veterinary clinics with recurring cartridge-based consumables revenue.
  • TRUVIEW The only fully automated digital microscope that prepares and digitizes hematology and cytology slides for review in minutes. Includes AI-powered diagnostic interpretation for automated analysis of hematology blood films with skin and ear cytology support.
  • VETGuardian PLUS Zero-touch vital signs remote monitor that ensures pets are safe and supervised from intake to discharge, featuring non-contact monitoring, live video with night vision, and thermal imaging capabilities for veterinary clinics.
  • SonoView Diagnostic platform that is part of ZOM-Dx portfolio for veterinary ultrasound or imaging diagnostics.
  • Assisi LOOP Portable, versatile, drug-free tPEMF therapy device clinically proven to decrease pain and inflammation in pets. Part of Assisi's targeted pulsed electromagnetic field therapy product line for veterinary use.
  • Loop Lounge Rechargeable therapy pad offering total body drug-free relief from pain and inflammation for cats and dogs of all sizes using tPEMF technology.
  • DentaLOOP Specialized tPEMF therapy device engineered for treating dental and oral pain in pets, applying proven Assisi LOOP technology in a design specifically for oral applications.
  • Calmer Canine Drug-free targeted PEMF therapy device clinically proven to offer long-term relief from canine separation anxiety.
  • PulseVet Shock Wave System Leading veterinary shock wave therapy device for regeneration, featuring swivel screen, Bluetooth operation, and preset treatment parameters. Backed by over 20 years of clinical research supporting shock wave therapy effectiveness.
  • VETIGEL Hemostatic Gel Plant-based hemostatic gel that stops bleeding in less than ten seconds, potentially reducing blood loss, anesthesia time, and improving patient outcomes. Supplied in pre-filled syringes ready for immediate use in veterinary surgery.

Quantifiable outcome

  • 68% gross margin achieved in 2025
  • +4 more outcomes

Companies that use Zomedica

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Zomedica technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature7 records

Zomedica partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor and core.

  • Fear Free, LLCminorGTM or Marketing Partner · 25 June 2026Renewed alliance with Fear Free, LLC to continue promoting low-stress veterinary care and pet wellbeing through Assisi Loop tPEMF therapy products. Partnership focuses on educating veterinary professionals on stress-reducing protocols and expanding awareness of non-invasive treatment options.
  • United States Eventing Association (USEA)minorGTM or Marketing Partner · 20 May 2026Renewed sponsorship agreement maintaining PulseVet's designation as the 'Official Shock Wave of the USEA' for another year. Partnership supports USEA programs focused on educating and celebrating riders, owners, trainers, and veterinarians within the sport of Eventing.
  • Boehringer Ingelheim Animal Health USA Inc.coreStrategic or Co-development Partner · 18 March 2026Strategic collaboration to integrate Zomedica's TRUFORMA diagnostic platform into Boehringer Ingelheim's idPPID awareness and testing program for pituitary pars intermedia dysfunction in horses. Boehringer will reimburse participating veterinarians for diagnostic testing, expand Zomedica's installed base, and drive recurring cartridge revenue. PPID affects approximately 20-25% of horses over 15 years of age.
  • Boehringer Ingelheim Animal HealthcoreStrategic or Co-development Partner · 18 March 2026Collaboration where Boehringer Ingelheim will reimburse veterinarians for diagnostic testing performed with Zomedica's TRUFORMA platform and provide no-cost analyzer placements in equine veterinary practices, accelerating TRUFORMA adoption.
  • MoichorcoreChannel Partner/ Reseller/ Distributor · 25 February 2026Commercial distribution agreement with Moichor, a veterinary pathology services provider, for TRUVIEW digital microscopy platform. Co-branded systems integrate Moichor's proprietary AI engine and board-certified pathology services for point-of-care veterinary customers nationwide, spanning companion animal and exotic animal practices.
  • Rahm Sensor DevelopmentminorOEM/ Whitelabel/ Licensing Partner · 22 January 2026Contract manufacturing and services agreement to manufacture Cell-Guardian, a personnel monitoring device for high-risk environments such as correctional settings. Zomedica leverages existing manufacturing infrastructure to generate contract-based revenue and improve asset utilization.
  • Grovet b.v.coreChannel Partner/ Reseller/ Distributor · 15 October 2025Expanded distribution agreement with Grovet b.v. to include Zomedica's diagnostic and therapeutic device products across the European Union, strengthening Zomedica's presence in the European veterinary market.
  • UXRcoreChannel Partner/ Reseller/ Distributor · 10 September 2025Expanded distribution agreement with UXR in Canada for Zomedica's diagnostic and therapeutic products, expanding market reach in the Canadian veterinary market.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Zomedica competitors and assessment

Company assessment

Direct peers

  • IDEXX Laboratories: IDEXX is the dominant veterinary diagnostics company with reference lab services, in-clinic analyzers (Catalyst, ProCyte, SNAP), and a broad assay menu. It is the primary competitive benchmark for Zomedica's TRUFORMA and TRUVIEW platforms, both directly and via former Zomedica executives with IDEXX backgrounds.
  • Antech Diagnostics (Mars Veterinary Health): Antech is the largest veterinary reference laboratory in North America and offers in-clinic diagnostics, imaging, and teleconsultation. Several Zomedica leaders (Paul Tye, Adrienne Bricaud) previously held senior roles at Antech, underscoring the direct competitive and customer overlap with Zomedica's diagnostic offerings.
  • Heska (now part of Mars Petcare): Heska specialized in veterinary in-clinic diagnostics (chemistry, hematology, immunoassay) and point-of-care testing before being acquired by Mars Petcare. It is a direct competitor to Zomedica's TRUFORMA platform and shares target customers (US companion animal clinics).
  • Covetrus: Covetrus is a leading distributor of veterinary products, services, and technologies, including in-clinic diagnostic platforms. Comparable to Zomedica on the distribution side of the veterinary diagnostic value chain and a potential channel partner or competitive threat to direct sales.

Broad incumbents

  • Zoetis: Zoetis is the world's largest animal health company with diagnostics, devices, pharmaceuticals, and vaccines across companion and livestock animals. Zomedica's VP of Corporate & Strategic Partnerships came from Zoetis, and Zoetis represents both a competitor (in therapeutic devices and diagnostics) and a potential strategic acquirer.
  • Elanco Animal Health: Elanco is a major global animal health company offering companion animal and livestock therapeutics, vaccines, and diagnostics. It is a broad incumbent comparable to Zomedica's therapeutic device and diagnostic portfolio, with substantially greater scale and distribution reach.
  • Dechra Pharmaceuticals: Dechra (acquired by EQT) is a specialty veterinary pharmaceuticals company focused on companion animal endocrinology, dermatology, and pain management. Its pain-management focus is comparable to Zomedica's Assisi tPEMF and PulseVet therapeutic franchises.
  • Virbac: Virbac is a global animal health company providing pharmaceuticals, vaccines, and diagnostics for companion and production animals. Comparable to Zomedica's equine and companion animal therapeutic portfolio, though with a much broader product range and geographic footprint.
  • Vetoquinol: Vetoquinol is a French veterinary pharmaceutical company specializing in companion animal therapeutics with growing presence in the US. Comparable to Zomedica on equine and companion animal therapeutic devices, though primarily a pharmaceutical rather than device company.

Emerging players

  • PetIQ: PetIQ is a US pet health and wellness company offering veterinary products, OTC supplements, and clinic services. While focused on different categories (preventives and wellness), it overlaps with Zomedica on the broader US companion animal health opportunity and similar end-customer base of pet owners and vets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Zomedica social profiles

Digital presence

Zomedica compliance and trust

Trust signal

Compliance5 records

Zomedica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Zomedica leadership team

Management profile

Number of profiles

Profiles19 records

Zomedica subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Zomedica funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Zomedica M&A and investment

M&A and investment

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zomedica

What does Zomedica do?

Zomedica develops, manufactures, and sells diagnostic and therapeutic medical devices for veterinary clinics treating companion animals (dogs, cats) and equine patients. Its product portfolio includes point-of-care biosensor diagnostic platforms (TRUFORMA), automated digital cytology microscopes (TRUVIEW), zero-touch patient vital signs monitors (VETGuardian PLUS), targeted pulsed electromagnetic field therapy devices (Assisi LOOP line), shock wave therapy systems (PulseVet), and hemostatic gels (VETIGEL). Revenue is generated through instrument placements combined with recurring consumable cartridge sales, alongside therapeutic device sales.

Is Zomedica a public or private company?

Zomedica is a public company. It is classified as public and is currently operating.

When was Zomedica founded?

Zomedica was founded in 2016. It employs 101 to 250 people.

Where is Zomedica based?

Zomedica is headquartered in Ann Arbor, United States, in the North America region.

How does Zomedica make money?

Three revenue lines are on record. Diagnostic Equipment and Consumables are the primary driver. The others are therapeutic Devices and contract Manufacturing Services.

Who are Zomedica's main competitors?

Direct peers on record are IDEXX Laboratories, Antech Diagnostics (Mars Veterinary Health), Heska (now part of Mars Petcare) and Covetrus. Broad incumbents are Zoetis, Elanco Animal Health, Dechra Pharmaceuticals, Virbac and Vetoquinol. PetIQ is listed as an emerging player.

Does Zomedica have an API?

No public API is recorded for Zomedica.

What industry is Zomedica in?

Zomedica's product category is Veterinary Diagnostics and Therapeutics. Its primary akta.pro industry code is HLAMAEAA, Companion Animal Therapeutics (Rx), with a secondary code of HLAMAEAC, Equine Therapeutics (Rx). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Markets DailyZomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) Stock Falls 6.6% – What’s Next?Zomedica Pharmaceuticals Corp. shares fell 6.6% on Wednesday, trading as low as C$0.28 with 4,800 shares exchanged. The veterinary diagnostic firm's lead candidate is ZM-007, an oral metronidazole for acute diarrhea in small dogs, and it is developing other veterinary drugs.Seeking AlphaZomedica Corp. (ZOMDF) Inside Marketing: How Demand Creation Drives Revenue and Supports Distinct Product Portfolios TranscriptZomedica Corp. held an investor webinar on September 25, 2026, detailing its marketing organization's demand-creation process. The company's strategy focuses on three phases: land, deepen, and expand, supporting two distinct product portfolios. The webinar also covered the company's mission and a five-pillar framework.MorningstarZomedica Announces "Fourth Friday at Four" Webinar on September 25, 2026: Inside Zomedica’s Marketing Engine: How Demand Becomes RevenueZomedica announced its September 25, 2026 investor webinar on its marketing engine, covering how demand becomes revenue across its diagnostic and therapeutic portfolios. The company reported 2025 revenue of $32 million and $18 million through June 2026, with $44 million in liquidity.BioSpaceZomedica Announces “Fourth Friday at Four” Webinar on September 25, 2026: Inside Zomedica’s Marketing Engine: How Demand Becomes RevenueZomedica announced its September 25, 2026, investor webinar on its marketing engine, covering how demand becomes revenue across diagnostics and therapeutics. The company reported 2025 revenue of $32 million and $18 million through June 2026, with $44 million in liquidity.Seeking AlphaZomedica Corp. (ZOMDF) Q2 2026 Earnings Call TranscriptZomedica opened its Fourth Friday at Four investor webinar on August 28, 2026, titled "Zomedica International, Building a Global Platform for Veterinary Innovation," outlining the company's strategy, partners and global growth opportunity. The presentation introduced the company's mission to deliver diagnostic and therapeutic technologies for veterinarians, guided by five pillars, though the transcript cuts off before those pillars are detailed.TradingViewZOMDF: International sales and recurring revenue growth are accelerating global profitability progressZomedica Corp. reported Q2 2026 sales up 37% overall and 17% internationally, driven by international expansion. The asset-light distribution model and recurring revenue from consumables support progress toward cash flow breakeven and profitability in 2027.Ticker ReportZomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) Trading Down 6.6% – Here’s What HappenedZomedica Pharmaceuticals Corp. shares fell 6.6% during Wednesday trading, dropping to C$0.28 from the previous close of C$0.30. The stock saw increased volume with approximately 4,800 shares changing hands, a 68% rise from the average session volume. The company currently has a market capitalization of C$36.73 million and is developing veterinary pharmaceutical candidates.MorningstarZomedica Announces Strategic Collaboration with Boehringer Ingelheim Animal Health Canada Inc. to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) PlatformZomedica announced a collaboration with Boehringer Ingelheim Animal Health Canada to expand equine endocrine diagnostic testing using its TRUFORMA platform, starting with the fall testing season. The program provides free TRUFORMA analyzers and diagnostic kits to participating equine practices, aiming to increase installed base and recurring revenue. PPID affects 20-25% of horses over 15 years old.FinancialContent Business PageZomedica Announces "Fourth Friday at Four" Webinar on August 28, 2026: Zomedica International: Building a Global Platform for Veterinary InnovationZomedica Corp. announced its "Fourth Friday at Four" investor webinar, scheduled for August 28, 2026, focusing on the company's international expansion strategy in veterinary healthcare. The webinar aims to provide insights into Zomedica's global market opportunities, distribution partnerships, and the leadership driving growth across multiple continents. This event underscores the company's commitment to building a scalable commercial operation outside North America as it seeks to enhance its offerings globally.Stock TitanZomedica Sets Aug. 28 Webinar on Global ExpansionZomedica announced a webinar scheduled for August 28, 2026, to showcase its international expansion strategy, including distributor infrastructure and global market opportunities. The company is actively building a global presence across multiple continents with a focus on veterinary diagnostics and therapeutic products.